We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 14, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Adobe Inc. (ADBE - Free Report) , AstraZeneca PLC (AZN - Free Report) , Intel Corp. (INTC - Free Report) , Morgan Stanley (MS - Free Report) and EOG Resources, Inc. (EOG - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Adobe, AstraZeneca and Intel
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE - Free Report) , AstraZeneca PLC (AZN - Free Report) and Intel Corp. (INTC - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Adobe's shares have outperformed the Zacks Computer - Software industry over the year-to-date period (+88.3% vs. +56.3%). The company is benefiting from strong demand for its creative products. The company's Creative Cloud, Document Cloud and Adobe Experience Cloud products are driving the top-line growth.
Rising subscription revenues and solid momentum across the mobile apps are major positives. Additionally, growth in emerging markets and robust online video creation demand remain tailwinds. Additionally, solid demand for Adobe's commerce offerings and growing adoption of Acrobat is a plus.
The Zacks analts remain optimistic about Adobe's market position, compelling product lines and continued innovation. However, the ongoing tensions between Russia and Ukraine remain headwinds for Digital Media segment. Also, high acquisition expenses do not bode well for its margin expansion.
Shares of AstraZeneca have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-7.3% vs. +5.6%). The company's diabetes franchise faces stiff competition while pricing pressure hurts sales in the respiratory unit. Sales have slowed down in its key market, China.
Nevertheless, AstraZeneca has a diverse product portfolio and a global footprint. Its key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra and Farxiga should keep driving revenues. AstraZeneca's pipeline is strong, with important phase III data readouts lined up.
It has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets. Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period
Intel's shares have outperformed the Zacks Semiconductor - General industry over the past six months (+24.6% vs. +9.1%). The company is focusing on establishing an advanced semiconductor manufacturing ecosystem and has expanded global production capabilities under its IDM 2.0 (integrated device manufacturing) strategy.
It remains on track with its 5N4Y (five nodes in four years) program in order to regain transistor performance and power performance leadership by 2025. Market diversification and healthy momentum in data center business are tailwinds. The foundry services are gaining traction while the launch of glass substrates for advanced packaging of chips is a positive.
The buyout of Mobileye has helped the company to rapidly penetrate the autonomous car technology market. However, weak demand trends and sluggish recovery in China are hurting sales to some extent. Macroeconomic challenges, inventory adjustments and intense market volatility are straining margins.
Other noteworthy reports we are featuring today include Morgan Stanley (MS - Free Report) and EOG Resources, Inc. (EOG - Free Report) .
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources
For Immediate Release
Chicago, IL – December 14, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Adobe Inc. (ADBE - Free Report) , AstraZeneca PLC (AZN - Free Report) , Intel Corp. (INTC - Free Report) , Morgan Stanley (MS - Free Report) and EOG Resources, Inc. (EOG - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Adobe, AstraZeneca and Intel
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE - Free Report) , AstraZeneca PLC (AZN - Free Report) and Intel Corp. (INTC - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Adobe's shares have outperformed the Zacks Computer - Software industry over the year-to-date period (+88.3% vs. +56.3%). The company is benefiting from strong demand for its creative products. The company's Creative Cloud, Document Cloud and Adobe Experience Cloud products are driving the top-line growth.
Rising subscription revenues and solid momentum across the mobile apps are major positives. Additionally, growth in emerging markets and robust online video creation demand remain tailwinds. Additionally, solid demand for Adobe's commerce offerings and growing adoption of Acrobat is a plus.
The Zacks analts remain optimistic about Adobe's market position, compelling product lines and continued innovation. However, the ongoing tensions between Russia and Ukraine remain headwinds for Digital Media segment. Also, high acquisition expenses do not bode well for its margin expansion.
(You can read the full research report on Adobe here >>>)
Shares of AstraZeneca have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-7.3% vs. +5.6%). The company's diabetes franchise faces stiff competition while pricing pressure hurts sales in the respiratory unit. Sales have slowed down in its key market, China.
Nevertheless, AstraZeneca has a diverse product portfolio and a global footprint. Its key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra and Farxiga should keep driving revenues. AstraZeneca's pipeline is strong, with important phase III data readouts lined up.
It has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets. Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period
(You can read the full research report on AstraZeneca here >>>)
Intel's shares have outperformed the Zacks Semiconductor - General industry over the past six months (+24.6% vs. +9.1%). The company is focusing on establishing an advanced semiconductor manufacturing ecosystem and has expanded global production capabilities under its IDM 2.0 (integrated device manufacturing) strategy.
It remains on track with its 5N4Y (five nodes in four years) program in order to regain transistor performance and power performance leadership by 2025. Market diversification and healthy momentum in data center business are tailwinds. The foundry services are gaining traction while the launch of glass substrates for advanced packaging of chips is a positive.
The buyout of Mobileye has helped the company to rapidly penetrate the autonomous car technology market. However, weak demand trends and sluggish recovery in China are hurting sales to some extent. Macroeconomic challenges, inventory adjustments and intense market volatility are straining margins.
(You can read the full research report on Intel here >>>)
Other noteworthy reports we are featuring today include Morgan Stanley (MS - Free Report) and EOG Resources, Inc. (EOG - Free Report) .
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.